Printed from Voxsanity (voxsanity.com.au) — NCT07101627 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07101627
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 or older (any gender).
- People who have been diagnosed with metastatic lung cancer confirmed by laboratory tissue testing.
- People currently receiving a platinum- or gemcitabine-based chemotherapy treatment given in 21-day cycles, with at least 2 more cycles planned.
- People with a general health/activity level score of 0–2 on a standard scale used by doctors (called ECOG PS), meaning someone who is fully active to someone who is up and about more than half the day (confirm with trial site).
- People whose platelet count dropped below 75 × 10⁹/L during a previous cycle of the same chemotherapy treatment.
- People whose platelet count is between 100 and 200 × 10⁹/L at the time of joining the trial.
- People whose bone marrow is producing enough blood cells — specifically, a white blood cell count (ANC) of at least 1.5 × 10⁹/L and haemoglobin of at least 8 g/dL.
- People whose liver and kidney function are within acceptable ranges as measured by standard blood tests (confirm specific values with trial site).
- People whose blood clotting function is within acceptable ranges as measured by standard tests (confirm with trial site).
- People expected to live for at least 3 more months.
- Women who could become pregnant must have a negative blood pregnancy test within 7 days before the first dose, must not be breastfeeding, and must agree to use effective contraception during the trial and for 7 days after the last dose; men whose partners could become pregnant must either be surgically sterilised or agree to use effective contraception during the trial and for 7 days after the last dose, and must not donate sperm during the study.
- People who are willing to join voluntarily, sign a consent form, and agree to attend follow-up appointments as required.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Women who are pregnant or breastfeeding.
- People who are unable to understand what the study involves or who are unable to give informed consent.
- People who have a blood or bone marrow disorder such as leukaemia, primary immune thrombocytopenia, myeloproliferative disorders, multiple myeloma, or myelodysplastic syndrome.
- People who have had a condition causing low platelet counts — other than as a result of cancer treatment — within the 6 months before screening, including conditions such as chronic liver disease, an enlarged spleen, or infection.
- People with an active infection that is not under control.
- People whose cancer has spread into the bone marrow.
- People who have had a blood clot or related event (such as stroke, mini-stroke, heart attack, deep vein thrombosis, or pulmonary embolism) within the 6 months before screening, or who have symptoms or a history suggesting a tendency to form blood clots.
- People with serious heart conditions, including severe heart failure, a heart rhythm problem requiring medication, a heart rhythm problem known to raise the risk of blood clots (such as atrial fibrillation), or an abnormal heart electrical reading (prolonged QTc interval) within the 3 months before screening.
- People whose low platelet count is caused by something other than their cancer treatment.
- People with a known allergy to TPO (thrombopoietin, a substance that helps the body make platelets).
- People who have serious bleeding symptoms or a clear tendency to bleed, such as bleeding in the stomach, intestines, or brain.
- People currently taking other medications or supplements that may affect platelet counts (including certain traditional medicines, platelet-boosting drugs, or antiplatelet drugs).
- People whom the trial doctor judges to be unsuitable for the study for other reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 13816756732
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
30 April 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Incidence of Grade 3 and Higher Thrombocytopenia
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.